on Theranexus (EPA:ALTHX)
THX Pharma Announces Webinar on Strategic Agreement with Biocodex
THX Pharma, known for its focus on rare neurological diseases, will host a webinar on February 17 to discuss its strategic partnership with Biocodex. This agreement involves the worldwide development and commercialization of Batten-1 and TX01 in North America, with a potential value of €173 million.
During the webinar, CEO Mathieu Charvériat and Deputy CEO Julien Veys will outline the terms of the licensing agreement and set forth the company's future plans, strategic milestones, and operational priorities within this partnership.
Interested parties can join the webinar through the provided link. This development marks a significant step for THX Pharma in its mission to innovate treatments for rare neurological diseases.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news